Zacks: Brokerages Expect Maximus, Inc. (MMS) Will Announce Earnings of $0.77 Per Share
Equities research analysts forecast that Maximus, Inc. (NYSE:MMS) will post earnings of $0.77 per share for the current fiscal quarter, according to Zacks Investment Research. Five analysts have made estimates for Maximus’ earnings, with the highest EPS estimate coming in at $0.78 and the lowest estimate coming in at $0.75. Maximus also posted earnings per share of $0.77 in the same quarter last year. The company is scheduled to report its next quarterly earnings results on Thursday, November 9th.
According to Zacks, analysts expect that Maximus will report full-year earnings of $3.13 per share for the current financial year, with EPS estimates ranging from $3.12 to $3.14. For the next financial year, analysts forecast that the company will post earnings of $3.22 per share, with EPS estimates ranging from $3.15 to $3.30. Zacks’ EPS averages are an average based on a survey of research analysts that that provide coverage for Maximus.
Maximus (NYSE:MMS) last posted its quarterly earnings results on Thursday, August 3rd. The health services provider reported $0.79 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.76 by $0.03. Maximus had a net margin of 8.43% and a return on equity of 25.08%. The company had revenue of $600.40 million for the quarter, compared to the consensus estimate of $614.12 million. During the same period last year, the firm posted $0.79 EPS. The company’s revenue for the quarter was down 2.7% on a year-over-year basis.
Several equities research analysts have issued reports on MMS shares. Robert W. Baird started coverage on shares of Maximus in a report on Sunday, September 3rd. They issued a “neutral” rating on the stock. Canaccord Genuity lowered shares of Maximus from a “buy” rating to a “hold” rating and set a $62.00 price target on the stock. in a report on Tuesday, July 4th. KeyCorp reissued a “sector weight” rating on shares of Maximus in a report on Thursday, May 25th. BidaskClub lowered shares of Maximus from a “strong-buy” rating to a “buy” rating in a report on Thursday, July 6th. Finally, Zacks Investment Research lowered shares of Maximus from a “hold” rating to a “sell” rating in a report on Tuesday, July 18th. One equities research analyst has rated the stock with a sell rating and nine have assigned a hold rating to the company. Maximus currently has a consensus rating of “Hold” and an average price target of $62.43.
In other news, Director Raymond B. Ruddy sold 25,000 shares of the company’s stock in a transaction dated Monday, September 11th. The shares were sold at an average price of $62.68, for a total value of $1,567,000.00. Following the sale, the director now owns 227,552 shares of the company’s stock, valued at approximately $14,262,959.36. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, General Counsel David Francis sold 1,000 shares of the company’s stock in a transaction dated Friday, June 23rd. The stock was sold at an average price of $63.15, for a total transaction of $63,150.00. Following the completion of the sale, the general counsel now directly owns 16,715 shares in the company, valued at approximately $1,055,552.25. The disclosure for this sale can be found here. In the last ninety days, insiders sold 133,403 shares of company stock worth $8,153,731. 3.10% of the stock is owned by insiders.
Institutional investors and hedge funds have recently bought and sold shares of the company. Neuburgh Advisers LLC grew its holdings in shares of Maximus by 1.9% in the 1st quarter. Neuburgh Advisers LLC now owns 1,696 shares of the health services provider’s stock worth $105,000 after purchasing an additional 32 shares during the last quarter. Acrospire Investment Management LLC lifted its position in Maximus by 183.3% during the 1st quarter. Acrospire Investment Management LLC now owns 1,700 shares of the health services provider’s stock worth $106,000 after buying an additional 1,100 shares in the last quarter. Glen Harbor Capital Management LLC lifted its position in Maximus by 1.9% during the 1st quarter. Glen Harbor Capital Management LLC now owns 2,332 shares of the health services provider’s stock worth $145,000 after buying an additional 44 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in Maximus by 10.2% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,367 shares of the health services provider’s stock worth $148,000 after buying an additional 220 shares in the last quarter. Finally, First Bank & Trust lifted its position in Maximus by 4.2% during the 2nd quarter. First Bank & Trust now owns 2,507 shares of the health services provider’s stock worth $157,000 after buying an additional 101 shares in the last quarter. 97.23% of the stock is currently owned by institutional investors and hedge funds.
Shares of Maximus (MMS) traded down 0.71% during mid-day trading on Thursday, reaching $62.92. 178,057 shares of the company traded hands. The stock has a market capitalization of $4.08 billion, a PE ratio of 20.17 and a beta of 1.37. Maximus has a 52-week low of $43.69 and a 52-week high of $64.97. The stock’s 50 day moving average is $60.63 and its 200 day moving average is $61.43.
The company also recently announced a quarterly dividend, which was paid on Thursday, August 31st. Stockholders of record on Tuesday, August 15th were issued a $0.045 dividend. This represents a $0.18 annualized dividend and a dividend yield of 0.29%. The ex-dividend date was Friday, August 11th. Maximus’s payout ratio is 5.73%.
Maximus Company Profile
MAXIMUS, Inc provides business process services (BPS) to government health and human services agencies. The Company operates through three segments: U.S. Federal Services, Health Services and Human Services. The U.S. Federal Services segment provides BPS and program management for large government programs, independent health review and appeals services for both the United States Federal Government, and state-based programs and technology solutions for civilian federal programs.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Maximus Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Maximus Inc. and related companies with MarketBeat.com's FREE daily email newsletter.